Search company, investor...



Other Investors | Alive

About AlphaGEN

The company are developing siRNA drugs targeting a control factor for HIF (hypoxia-inducible factor), which is one of the main factors involved in angiogenesis. The company have found that siRNA can promote angiogenesis by inducing expression of several angiogenic factors simultaneously by preventing breakdown of HIF inside the cell. It is therefore expected that delivery of siRNA to disease-affected sites can efficiently induce angiogenesis, leading to a in treatment for obstructive arteriosclerosis.

Headquarters Location

3-29 Kioicho Chiyoda-ku




Missing: AlphaGEN's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AlphaGEN's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

AlphaGEN Patents

AlphaGEN has filed 1 patent.

The 3 most popular patent topics include:

  • Abstract algebra
  • Binary operations
  • Cannabinoids
patents chart

Application Date

Grant Date


Related Topics




Wood products, Engineered wood, Wood, Woodworking, Electric power distribution


Application Date


Grant Date



Related Topics

Wood products, Engineered wood, Wood, Woodworking, Electric power distribution



Latest AlphaGEN News

La-Z-Boy to Occupy Philadelphia’s Old U.S. Motors Building

Mar 9, 2016

Posted: Wed 1:11 PM, Mar 09, 2016 / Headlines List / Article The old U.S. Motors bulding has been vacant since 2011, when La-Z-Boy and Taylor Machine Works moved out in order for AlphaGen to move in. In 2010, AlphaGen signed a memorandum of understanding pledging to create 200 jobs by November 2015 in exchange for $1 million of renovations to the old U.S. Motors building. AlphaGen never generated those jobs. Now, La-Z-Boy plans to come back in and occupy the building. "Some things work out, some don't. That's the atmosphere of this business. We were hopeful to do something different, but it just didn't work out. Right now, we are trying to solidify the area and get some activity out there," says Mayor Young. In November, the city was left footing the bill since AlphaGen never created those jobs. The city was given time to find a replacement before having to pay back the $1 million grant. "We are working on creating jobs, creating things there. There are some ideas circulating that would help put some bodies in the place. Of course, La-Z-Boy will have their employees there and hopefully there will be some other things will spring out of that," says Mayor Young. Mayor Young says the city and state are still concerned with job creation because he doesn't expect La-Z-Boy to create more than a handful of jobs since the building will be used as warehouse space rather than manufacturing. "With all of the other things going on in the city, I think we are on a good road to financial stability and creating some opportunities for our people," says Mayor Young.

AlphaGEN Frequently Asked Questions (FAQ)

  • What is AlphaGEN's latest funding round?

    AlphaGEN's latest funding round is Other Investors.

  • Who are the investors of AlphaGEN?

    Investors of AlphaGEN include Mitsubishi UFJ Capital.

  • Who are AlphaGEN's competitors?

    Competitors of AlphaGEN include CoMentis, EpiCept, Micromet, Nuon Therapeutics, Proteolix and 12 more.

Compare AlphaGEN to Competitors

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Stemina Biomarker Discovery Logo
Stemina Biomarker Discovery

Stemina Cell Discovery discovers and validates small molecules as biomarkers for high-throughput drug screening and disease diagnostics using an all human system comprised of stem cells and the company's metabolomics platform. Metabolomics aims to enable the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progress of disease or toxic response. Stemina aims to provide compound screening and diagnostic development for the pharmaceutical and biotechnology industries and academia under contract services or joint discovery agreements.


Altheos, Inc. is an early-stage biopharmaceutical company focused on the identification and development of promising well-differentiated novel small molecule drugs for unmet medical needs. Altheos, Inc. was co-founded in 2009 by two experienced pharmaceutical drug development executives and entrepreneurs, Henry H. Hsu, M.D. and M. (Ken) Kengatharan, Ph.D. The company is headquartered in South San Francisco, California.


NovoCell, Inc./BresaGen is a stem cell engineering company dedicated to creating, delivering, and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Novocell uses its cell encapsulation technology and expertise in cell implantation to develop a renewable source of specialized cells for the treatment of cellular diseases. Bresagen represents a division of Novocell's research operation.


AmpliMed Corporation, a clinical-stage pharmaceutical company founded by oncologists, is focused on a lead compound, Amplimexon, which per AmpliMed has shown early evidence of efficacy and low levels of toxicity. The company is focused on the development of small-molecule oncology drugs with novel mechanisms of action.

Oculus Innovative Sciences

Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform features a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized in the United States, Europe, India, China and Mexico for the treatment of infected wounds. The solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.